Electromed, Inc. (ELMD) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Electromed, Inc. Do?
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota. Electromed, Inc. (ELMD) is classified as a micro-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Kathleen S. Skarvan and employs approximately 160 people, headquartered in NEW PRAGUE, Minnesota. With a market capitalization of $196M, ELMD is one of the notable companies in the Healthcare sector.
Electromed, Inc. (ELMD) Stock Rating — Hold (April 2026)
As of April 2026, Electromed, Inc. receives a Hold rating with a composite score of 41.4/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.ELMD ranks #1,783 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Electromed, Inc. ranks #183 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
ELMD Stock Price and 52-Week Range
Electromed, Inc. (ELMD) currently trades at $24.41. The 52-week high for ELMD is $30.73, which means the stock is currently trading -20.6% from its annual peak. The 52-week low is $17.73, putting the stock 37.7% above its annual trough. Recent trading volume was 0 shares, suggesting relatively thin trading activity.
Is ELMD Overvalued or Undervalued? — Valuation Analysis
Electromed, Inc. (ELMD) carries a value factor score of 47/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 22.47x, compared to the Healthcare sector average of 23.63x — a discount of 5%. The price-to-book ratio stands at 4.33x, versus the sector average of 2.75x. The price-to-sales ratio is 2.91x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, ELMD trades at 17.94x EV/EBITDA, versus 6.34x for the sector.
Overall, ELMD's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Electromed, Inc. Profitability — ROE, Margins, and Quality Score
Electromed, Inc. (ELMD) earns a quality factor score of 50/100, indicating solid business quality with consistent operational execution. The return on equity (ROE) is 19.3%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 16.0% versus the sector average of -33.1%.
On a margin basis, Electromed, Inc. reports gross margins of 78.1%, compared to 71.5% for the sector. The operating margin is 16.1% (sector: -66.1%). Net profit margin stands at 12.9%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 28.8% on a trailing basis, compared to 10.6% for the sector. The overall profitability profile is adequate, though there may be room for margin expansion.
ELMD Debt, Balance Sheet, and Financial Health
Electromed, Inc. has a debt-to-equity ratio of 21.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.86x, indicating strong short-term liquidity.
ELMD has a beta of 0.64, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Electromed, Inc. is 61/100, reflecting average volatility within the normal range for its sector.
Electromed, Inc. Revenue and Earnings History — Quarterly Trend
In TTM 2026, Electromed, Inc. reported revenue of $68M and earnings per share (EPS) of $0.33. Net income for the quarter was $9M. Gross margin was 78.1%. Operating income came in at $11M.
In Q2 2026, Electromed, Inc. reported revenue of $19M and earnings per share (EPS) of $0.33. Net income for the quarter was $3M. Gross margin was 78.4%. Revenue grew 16.3% year-over-year compared to Q2 2025. Operating income came in at $4M.
In Q1 2026, Electromed, Inc. reported revenue of $17M and earnings per share (EPS) of $0.26. Net income for the quarter was $2M. Gross margin was 78.1%. Revenue grew 15.1% year-over-year compared to Q1 2025. Operating income came in at $3M.
In FY 2025, Electromed, Inc. reported revenue of $64M and earnings per share (EPS) of $0.89. Net income for the quarter was $8M. Gross margin was 78.1%. Revenue grew 17.0% year-over-year compared to FY 2024. Operating income came in at $10M.
Over the past 8 quarters, Electromed, Inc. has demonstrated a growth trajectory, with revenue expanding from $55M to $68M. Investors analyzing ELMD stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
ELMD Dividend Yield and Income Analysis
Electromed, Inc. (ELMD) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.
ELMD Momentum and Technical Analysis Profile
Electromed, Inc. (ELMD) has a momentum factor score of 36/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 20/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
ELMD vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Electromed, Inc. (ELMD) ranks #183 out of 838 stocks based on the Blank Capital composite score. This places ELMD in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing ELMD against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ELMD vs S&P 500 (SPY) comparison to assess how Electromed, Inc. stacks up against the broader market across all factor dimensions.
ELMD Next Earnings Date
No upcoming earnings date has been announced for Electromed, Inc. (ELMD) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy ELMD? — Investment Thesis Summary
Electromed, Inc. presents a balanced picture with arguments on both sides. Momentum is weak at 36/100, a headwind for near-term performance. Low volatility (stability score 61/100) reduces downside risk.
In summary, Electromed, Inc. (ELMD) earns a Hold rating with a composite score of 41.4/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ELMD stock.
Related Resources for ELMD Investors
Explore more research and tools: ELMD vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ELMD head-to-head with peers: ELMD vs AZN, ELMD vs SLGL, ELMD vs VMD.